Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
US-9221812-B2 · Dec 29, 2015 · US
MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer
US10125099B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10125099-B2 |
| Application number | US-201615293055-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 13, 2016 |
| Priority date | Jul 26, 2011 |
| Publication date | Nov 13, 2018 |
| Grant date | Nov 13, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A pharmaceutical composition and method for treating brain cancer are provided. The method includes administering to a patient in need thereof an effective amount of one or more compounds that include moclobemide, clorgyline, clorgyline's Near-infra-red dye Monoamine Oxidase Inhibitor (NMI), and MHI 148-clorgyline, and their salt thereof. The composition and method are particularly effective in reducing the size of glioblastomas that are temozolomide (TMZ) resistant.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound comprising a salt of or the carboxylic acid thereof. 2. A pharmaceutical composition comprising the compound of claim 1 . 3. The pharmaceutical composition of claim 2 further comprising an excipient. 4. The pharmaceutical composition of claim 2 further comprising a physiologically acceptable carrier.
Assignees
Inventors
Classifications
Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin · CPC title
against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title
having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10125099B2 cover?
- A pharmaceutical composition and method for treating brain cancer are provided. The method includes administering to a patient in need thereof an effective amount of one or more compounds that include moclobemide, clorgyline, clorgyline's Near-infra-red dye Monoamine Oxidase Inhibitor (NMI), and MHI 148-clorgyline, and their salt thereof. The composition and method are particularly effective in…
- Who is the assignee on this patent?
- Univ Southern California
- What technology area does this patent fall under?
- Primary CPC classification C07D209/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).